There has been controversy about the ad Hims & Hers ran during the Super Bowl. And now an SEC filing says investors should be warned about risk if their ads are found to be non-compliant.
This is a reprint of an FDA Alert.
PSM’s new report shows that unregulated semaglutide and tirzepatide are slipping by FDA and CBP at the border. Semaglutide is no longer in shortage.
The Partnership for Safe Medicines today released a new report that found suspicious, unauthorized, and illegal ingredients for popular diabetes and obesity injectables (commonly known as weight loss drugs) are flooding into the U.S. from foreign sources despite U.S. laws forbidding them from coming through the border.
The Partnership for Safe Medicines applauds the Arkansas State Board of Pharmacy for utilizing new product verification technology for identifying illegitimate Ozempic quarantined by a pharmacy this week.
Mystery cosmetic injections allegedly harmed a client in Queens. PSM addressed a misleading drug ad for compounded weight loss medicine.
You could tell an American that they’re getting a compounded medicine and they would have no idea what that meant. That may be a legal disclosure, but that’s not good enough to protect patients who don’t know what the words mean.
PSM sent the following letter to the FDA’s Office of Prescription Drug Promotion (CDER) asking them to enforce the laws and guidelines that protect Americans from misleading advertising in the Hims&Hers Super Bowl ad.
PSM sent the attached letter to Fox Broadcasting, calling on them to withdraw the deeply troubling and misleading Hims&Hers Super Bowl ad.
Employees of the now-closed Chinese chemical company Hubei Amarvel Biotech were convicted at trial after shipping more than 200 kilograms of fentanyl precursor chemicals to the U.S. between November 2022 and June 2023.